Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions
Status:
Not yet recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
TECNO is a multicenter, prospective, randomized, open label, blinded endpoint (PROBE)
proof-of-concept trial evaluating if additional administration of intra-arterial Tenecteplase
(TNK) improves reperfusion in patients with incomplete mechanical thrombectomy (MT). For this
purpose, 156 adult participants experiencing an acute ischemic stroke due to a large vessel
occlusion with incomplete reperfusion with residual occlusions after MT will be randomly
assigned to receive 3mg intra-arterial (IA) TNK or best medical treatment. Recruitment will
occur at 20 academic tertiary stroke care centers in Switzerland, Spain, Belgium, and Germany
and patients are followed up for 90 days after the index event. Showing superiority for
reperfusion outcomes would have a major impact on the future management of stroke patients.